Genetically modified human natural killer cell lines
View Patent ↗The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ,TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
1. A NK-92 cell modified to express an Fc receptor and display it on its cell surface, wherein said NK-92 cell is available from American Type Culture Collection (ATCC) as Accession No. PTA-6670.
2. The cell of claim 1 , wherein the Fc receptor comprises CD16 (Fcγ RIII-A).
3. The cell of claim 1 , wherein the Fc receptor is an Fcγ RIII.
4. The cell of claim 1 , wherein the Fc receptor consists of a polypeptide sequence encoded by the polynucleotide sequence of SEQ ID NO:3 or SEQ ID NO:4.
5. The cell of claim 1 , wherein said NK-92 cell is modified by retroviral transduction to express said Fc receptor.
6. The cell of claim 4 wherein the nucleotide sequence of SEQ ID NO:3 encodes the polypeptide of SEQ ID NO:1.
7. The cell of claim 1 , wherein the NK-92 cell is modified by transfection to express said Fc receptor.